World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
67784
World Ranking
3692
National Ranking
367

Kevin J. Harrington publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kevin J. Harrington sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 888 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kevin J. Harrington D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kevin J. Harrington sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Kevin J. Harrington is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research primarily resides within the field of Medicine, with a strong focus on Oncology, Otorhinolaryngology, Immunology, Pulmonary and Respiratory Medicine, and Surgery.

The scientist has contributed extensively to topics such as Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Virus-based Gene Therapy Research, CAR-T Cell Therapy Research, Immunotherapy and Immune Responses, Lung Cancer Treatments and Mutations, and Cancer Research and Treatments.

Frequent co-authors working alongside Kevin J. Harrington include:

  • Alan Melcher
  • Lisa Licitra
  • Makoto Tahara
  • Pablo Nenclares
  • Robert I. Haddad

Kevin J. Harrington has published often in several scientific journals. Notable venues with multiple publications include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Radiotherapy and Oncology

Selected recent papers authored or co-authored by Harrington include:

  • "Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study," 2022, Journal of Clinical Oncology
  • "Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial," 2021, The Lancet Oncology
  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death," 2020, Journal for ImmunoTherapy of Cancer
  • "Inflammatory microenvironment remodelling by tumour cells after radiotherapy," 2020, Nature reviews. Cancer
  • "Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement," 2020, International Journal of Radiation Oncology*Biology*Physics

Best Publications

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

    Holly E. Barker;James T. E. Paget;Aadil A. Khan;Kevin J. Harrington

  • Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

    Christopher M Nutting;Christopher M Nutting;James P Morden;Kevin J Harrington;Kevin J Harrington;Teresa Guerrero Urbano

  • Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells.

    Cedric Gaggioli;Steven Hooper;Cristina Hidalgo-Carcedo;Robert Grosse

  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Ezra E W Cohen;Denis Soulières;Christophe Le Tourneau;Christophe Le Tourneau;Christophe Le Tourneau;José Dinis

  • Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts

    Fernando Calvo;Nil Ege;Araceli Grande-Garcia;Steven Hooper

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

    H Mehanna;M Robinson;A Hartley;A Kong

  • Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

    Martin McLaughlin;Emmanuel C. Patin;Malin Pedersen;Anna Wilkins

  • Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

    Kevin J. Harrington;Kevin J. Harrington;Sima Mohammadtaghi;Paul S. Uster;Daphne Glass

  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

    Jennifer C.C. Hu;Robert S. Coffin;Ceri J. Davis;Nicola J. Graham

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    Ezra E.W. Cohen;R. Bryan Bell;Carlo B. Bifulco;Barbara Burtness

  • Optimizing oncolytic virotherapy in cancer treatment.

    Kevin Harrington;Daniel J. Freeman;Beth Kelly;James Harper

  • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

    Nancy Y Lee;Robert L Ferris;Amanda Psyrri;Robert I Haddad

Frequent Co-Authors

Christopher M. Nutting
Christopher M. Nutting Royal Marsden NHS Foundation Trust
Alan Melcher
Alan Melcher Institute of Cancer Research
Richard G. Vile
Richard G. Vile Mayo Clinic
Peter Selby
Peter Selby University of Leeds
Matthew C. Coffey
Matthew C. Coffey Oncolytics Biotech (Canada)
Lisa Licitra
Lisa Licitra University of Milan
Timothy Kottke
Timothy Kottke Mayo Clinic
Robert I. Haddad
Robert I. Haddad Harvard University
Robert L. Ferris
Robert L. Ferris University of Pittsburgh
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean attending medical school. There are a variety of related online degrees and flexible career pathways in the healthcare sector, many of which can be pursued remotely and allow diverse entry points into the industry.

For example, him programs (Health Information Management) blend technology and healthcare, opening doors to administrative and data-driven roles. If you’re looking for a specialized but quick-to-enter field, exploring medical billing and coding cost can help you find affordable programs designed for certification in just months.

Those interested in patient care at an advanced level might consider nurse practitioner programs. These allow experienced nurses to step into primary or specialized care roles with greater autonomy. Entry-level nursing, on the other hand, is accessible through various nursing school online options which offer flexible, accredited training for LPNs, RNs, and more.

With a growing demand for healthcare professionals, these online pathways offer practical, cost-effective routes into rewarding, high-impact careers.

Best Scientists Citing Kevin J. Harrington

Trending Scientists